AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T20:28:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Insights Into The Cooper Companies (COO) Q2: Wall Street Projections for Key Metrics
Fri 23 May 25, 01:15 PMCiti shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
Thu 22 May 25, 01:18 PMCooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet
Tue 20 May 25, 08:15 PMCooper Companies Q2 Earnings Likely to Reflect Seasonal Trends
Tue 20 May 25, 11:48 AM2 Safe-and-Steady Stocks Worth Your Attention and 1 to Avoid
Mon 19 May 25, 04:39 AM1 Healthcare Stock Worth Investigating and 2 to Ignore
Fri 16 May 25, 04:38 AMXRAY or COO: Which Is the Better Value Stock Right Now?
Wed 14 May 25, 03:40 PMThe Cooper Companies, Inc. (COO): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
Wed 14 May 25, 11:47 AMCooperCompanies to Participate in the William Blair Growth Stock Conference
Thu 08 May 25, 08:15 PM| Breakdown | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
| Income before tax | 566.50M | 582.30M | 412.90M | 475.30M | 491.50M |
| Minority interest | - | - | - | - | - |
| Net income | 374.90M | 392.30M | 294.20M | 385.80M | 2944.70M |
| Selling general administrative | 1627.80M | 1533.70M | 1501.20M | 1342.20M | 1211.20M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2482.90M | 2595.70M | 2357.90M | 2139.60M | 1955.80M |
| Reconciled depreciation | 377.40M | 375.10M | 186.20M | 179.50M | 146.10M |
| Ebit | 630.40M | 696.60M | 518.20M | 507.60M | 505.80M |
| Ebitda | 1053.40M | 1071.70M | 704.40M | 712.10M | 660.70M |
| Depreciation and amortization | 423.00M | 375.10M | 186.20M | 204.50M | 154.90M |
| Non operating income net other | - | - | - | 25.00M | 8.80M |
| Operating income | 682.90M | 705.70M | 533.10M | 507.60M | 505.80M |
| Other operating expenses | 3409.50M | 3189.70M | 3060.10M | 2800.80M | 2416.70M |
| Interest expense | 100.00M | 114.30M | 105.30M | 57.30M | 23.10M |
| Tax provision | 191.60M | 190.00M | 118.70M | 89.50M | -2453.20000M |
| Interest income | - | - | - | 57.30M | 23.10M |
| Net interest income | -100.00000M | -114.30000M | -105.30000M | -57.30000M | -23.10000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 191.60M | 190.00M | 118.70M | 89.50M | -2453.20000M |
| Total revenue | 4092.40M | 3895.40M | 3593.20M | 3308.40M | 2922.50M |
| Total operating expenses | 1800.00M | 1890.00M | 1824.80M | 1632.00M | 1450.00M |
| Cost of revenue | 1609.50M | 1299.70M | 1235.30M | 1168.80M | 966.70M |
| Total other income expense net | -116.40000M | -123.40000M | -14.90000M | -32.30000M | -14.30000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 374.90M | 392.30M | 294.20M | 385.80M | 2944.70M |
| Net income applicable to common shares | - | - | - | 385.80M | 2944.70M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
| Total assets | 12394.80M | 12315.20M | 11658.90M | 11492.30M | 9606.20M |
| Intangible assets | 1586.30M | 1791.00M | 1710.30M | 1885.10M | 1271.50M |
| Earning assets | - | - | - | - | - |
| Other current assets | 320.80M | 324.20M | 238.80M | 208.90M | 179.30M |
| Total liab | 4155.70M | 4231.60M | 4107.90M | 4317.60M | 2664.20M |
| Total stockholder equity | 8238.90M | 8083.40M | 7551.00M | 7174.70M | 6942.00M |
| Deferred long term liab | - | - | - | 149.90M | 24.10M |
| Other current liab | 598.20M | 599.10M | 538.10M | 525.20M | 649.20M |
| Common stock | 21.80M | 21.70M | 5.40M | 5.40M | 5.40M |
| Capital stock | 21.80M | 21.70M | - | 5.40M | 5.40M |
| Retained earnings | 7643.30M | 7268.40M | 6876.10M | 6584.90M | 6202.10M |
| Other liab | - | - | - | 686.60M | 304.30M |
| Good will | 3853.40M | 3838.40M | 3624.50M | 3609.70M | 2574.00M |
| Other assets | - | - | - | 3031.00M | 2690.80M |
| Cash | 110.60M | 107.60M | 120.80M | 138.20M | 95.90M |
| Cash and equivalents | - | - | - | 138.20M | 95.90M |
| Total current liabilities | 1112.80M | 1022.80M | 969.00M | 1280.20M | 732.10M |
| Current deferred revenue | 127.90M | 129.90M | 123.60M | 93.60M | -161.40000M |
| Net debt | 2673.00M | 2476.10M | 2448.40M | 2625.20M | 1614.80M |
| Short term debt | 86.30M | 33.30M | 45.40M | 412.60M | 82.90M |
| Short long term debt | 47.10M | 32.20M | 45.40M | 412.60M | 82.90M |
| Short long term debt total | 2783.60M | 2583.70M | 2569.20M | 2763.40M | 1710.70M |
| Other stockholder equity | 980.30M | 1215.00M | 1123.10M | 1051.20M | 1075.80M |
| Property plant equipment | - | - | - | 1432.90M | 1604.60M |
| Total current assets | 2106.40M | 1951.50M | 1704.90M | 1533.60M | 1465.30M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 1679.90M | 3096.50M |
| Short term investments | - | - | - | - | - |
| Net receivables | 829.00M | 717.00M | 609.70M | 557.80M | 515.30M |
| Long term debt | 2455.70M | 2548.00M | 2523.80M | 2350.80M | 1396.10M |
| Inventory | 846.00M | 802.70M | 735.60M | 628.70M | 585.60M |
| Accounts payable | 300.40M | 260.50M | 261.90M | 248.80M | 161.40M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | 0.20M | 0.20M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -406.50000M | -421.70000M | -453.80000M | -466.80000M | -341.30000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 5.40M | 5.40M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | 6584.90M | 6202.10M |
| Treasury stock | - | - | - | - | -639.60000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 689.20M | 660.60M | 637.10M | 587.90M | 144.20M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 10288.40M | 10363.70M | 9954.00M | 9958.70M | 8140.90M |
| Capital lease obligations | 2.50M | 3.50M | - | 20.60M | 231.70M |
| Long term debt total | - | - | - | 2350.80M | 1396.10M |
| Breakdown | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
| Investments | - | -764.60000M | -449.00000M | 52.10M | -450.30000M |
| Change to liabilities | - | - | 5.50M | 20.70M | 31.40M |
| Total cashflows from investing activities | -372.90000M | -764.60000M | -449.00000M | -1831.20000M | -450.30000M |
| Net borrowings | -79.90000M | 5.60M | -180.80000M | 1278.80M | -309.90000M |
| Total cash from financing activities | -425.90000M | 39.20M | -173.90000M | 1193.70M | -311.40000M |
| Change to operating activities | - | - | -58.20000M | -70.00000M | -59.20000M |
| Net income | 374.90M | 392.30M | 294.20M | 385.80M | 2944.70M |
| Change in cash | 2.90M | -13.20000M | -17.70000M | 42.00M | -20.20000M |
| Begin period cash flow | 107.70M | 120.90M | 138.60M | 96.60M | 116.80M |
| End period cash flow | 110.60M | 107.70M | 120.90M | 138.60M | 96.60M |
| Total cash from operating activities | 796.10M | 709.30M | 607.50M | 692.40M | 738.60M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 423.00M | 413.80M | 367.70M | 346.10M | 309.30M |
| Other cashflows from investing activities | - | - | - | -1641.30000M | -235.90000M |
| Dividends paid | 0.00000M | 0.00000M | 3.00M | 3.00M | 3.00M |
| Change to inventory | -46.00000M | -59.30000M | -105.40000M | -40.40000M | -9.20000M |
| Change to account receivables | -120.30000M | -117.10000M | -60.20000M | -33.80000M | -75.50000M |
| Sale purchase of stock | -290.10000M | 8.30M | -23.00000M | -78.50000M | -24.80000M |
| Other cashflows from financing activities | -71.90000M | -30.30000M | 1783.00M | 1836.70M | -0.10000M |
| Change to netincome | - | - | 164.40M | 100.10M | -2397.90000M |
| Capital expenditures | 362.40M | 421.20M | 392.50M | 242.00M | 214.40M |
| Change receivables | - | - | - | -33.80000M | -75.50000M |
| Cash flows other operating | - | - | - | -86.10000M | -64.20000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | 54.90M | -23.10000M |
| Change in working capital | -284.80000M | -333.70000M | -218.80000M | -174.00000M | -149.90000M |
| Stock based compensation | 70.50M | 75.10M | 62.10M | 54.20M | 43.80M |
| Other non cash items | 147.80M | 118.00M | 57.60M | 26.40M | 92.90M |
| Free cash flow | 433.70M | 288.10M | 215.00M | 450.40M | 524.20M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COO The Cooper Companies, Inc |
1.68 2.78% | 62.02 | 34.69 | 14.95 | 3.16 | 1.57 | 3.73 | 14.30 |
| ISRG Intuitive Surgical Inc |
11.53 2.83% | 418.82 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 201.48 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
4.49 4.57% | 102.66 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
3.95 2.71% | 149.56 | 25.56 | 12.48 | 2.59 | 1.76 | 2.89 | 12.55 |
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
6101 Bollinger Canyon Road, San Ramon, CA, United States, 94583
| Name | Title | Year Born |
|---|---|---|
| Mr. Albert G. White III | Pres, CEO & Non-Independent Director | 1970 |
| Mr. Brian G. Andrews | Exec. VP, CFO & Treasurer | 1979 |
| Mr. Daniel G. McBride Esq. | Exec. VP & COO | 1964 |
| Mr. Agostino Ricupati | Sr. VP & Chief Accounting Officer | 1967 |
| Ms. Holly R. Sheffield | Pres of CooperSurgical, Inc. | 1971 |
| Mr. Kim Duncan | VP of Investor Relations & Risk Management | NA |
| Mr. Nicholas S. Khadder | Gen. Counsel & Corp. Sec. | 1974 |
| Mr. Juan Carlos Aragon | Pres of CooperVision Specialty EyeCare Division | NA |
| Mr. Gerard H. Warner III | Pres of CooperVision, Inc. | 1965 |
| Mr. Albert G. White III | President, CEO & Non-Independent Director | 1970 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...